Product nameAnti-Fibrinogen beta chain antibody [EPR3083]
See all Fibrinogen beta chain primary antibodies
DescriptionRabbit monoclonal [EPR3083] to Fibrinogen beta chain
Tested applicationsSuitable for: WB, Flow Cyt, ICC/IFmore details
Unsuitable for: IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to Human Fibrinogen beta chain aa 400-500 (C terminal).
Database link: P02675
- Human plasma, Human prostrate and Rat platelet lysates; HeLa cells
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab133359 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/2000. Detects a band of approximately 56 kDa (predicted molecular weight: 56 kDa).|
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||1/100 - 1/250.|
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGB are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This rare autosomal recessive disorder is characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=Patients with congenital fibrinogen abnormalities can manifest different clinical pictures. Some cases are clinically silent, some show a tendency toward bleeding and some show a predisposition for thrombosis with or without bleeding.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsConversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
- Information by UniProt
- Beta fibrinogen antibody
- Epididymis Secretory Sperm Binding Protein Li 78p antibody
- FGB antibody
All lanes : Anti-Fibrinogen beta chain antibody [EPR3083] (ab133359) at 1/1000 dilution
Lane 1 : Human plasma lysate
Lane 2 : Human prostate lysate
Lane 3 : Rat platelet lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 56 kDa
Actual band size : 56 kDa
Immunofluorescence analysis of Fibrinogen beta chain in HeLa cells, using ab133359 at a dilution of 1/100.